Key statistics

Is BMY a good stock to buy in 2026?

BMY stock presents an interesting case for investors, trading at a P/E ratio of 15.61x, notably below the Healthcare sector average of 21.1x. The Discounted Cash Flow (DCF) model suggests a significant undervaluation with a fair value of $288.83, indicating a 390.0% upside. While 46.3% of analysts rate BMY as a “Buy,” the overall consensus remains “Hold,” reflecting a mixed outlook for BMY valuation despite its apparent discount. Not investment advice.

2026 BMY price scenarios

Based on analyst consensus of $62.73 from 41 analysts. Not a prediction by Alert Invest.

About Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi

Under the leadership of CEO Christopher S. Boerner, Bristol-Myers Squibb operates with a substantial global workforce of 34,100 dedicated employees. The company’s distinctive strengths lie in its robust R&D capabilities, consistently bringing innovative biopharmaceutical products to market across critical therapeutic areas like oncology, hematology, and immunology. This strong focus on innovation and diversified portfolio helps BMY maintain its competitive standing in the highly dynamic healthcare sector.

BMY competitive moat and business analysis

Bristol-Myers Squibb (BMY) maintains a competitive advantage through its extensive intellectual property and a strong portfolio of patented drugs. While its net margin of 14.63% demonstrates solid operational efficiency, detailed Return on Equity (ROE) and Return on Invested Capital (ROIC) data are currently unavailable. Despite this, the inherent barriers to entry in drug development, including high R&D costs and stringent regulatory processes, contribute significantly to BMY’s economic moat, protecting its market share and profitability.

Regarding revenue breakdown, specific detailed segment and geographical data for fiscal year 2025 are not publicly provided at this time. However, the company’s broad product portfolio across therapeutic areas like oncology, cardiovascular, and immunology, coupled with a global sales presence, suggests diversified revenue streams. This diversification is crucial for mitigating risks associated with patent expirations and market shifts in individual product lines or regions.

BMY’s revenue growth currently stands at a modest -0.2%, indicating a challenging period possibly due to patent cliffs or increased competition for established drugs. This slight decline suggests that while the company’s core assets provide a stable base, it is actively working to replenish its pipeline and introduce new growth drivers to reverse this trend.

In the dynamic pharmaceutical industry, BMY faces competition from other large-cap drug manufacturers. Evaluating BMY stock requires a thorough comparison against peers in terms of pipeline strength, market share, and profitability metrics. While specific peer comparison data is not provided here, investors typically look at companies like Merck & Co. (MRK) and Pfizer (PFE) when assessing the broader competitive landscape within the Healthcare sector.

Bristol-Myers Squibb Company analyst rating

Based on 41 analysts. 46.3% rate BMY Buy or Strong Buy.

With 46.3% of analysts rating BMY as a ‘Buy’ or ‘Strong Buy’, this indicates a moderately positive sentiment within the analyst community for BMY stock. While not an overwhelming majority, it suggests a significant portion of experts see upside potential for Bristol-Myers Squibb Company within the competitive Healthcare sector.

Is BMY undervalued or overvalued?

When assessing BMY valuation, the company’s current P/E ratio of 15.61x stands out, being significantly lower than the Drug Manufacturers – General sector average of 21.1x. This indicates that BMY stock is trading at a discount compared to its industry peers on an earnings basis, which might appeal to value investors looking for potential opportunities in the Healthcare sector.

Further bolstering the case for BMY’s potential undervaluation is its Discounted Cash Flow (DCF) fair value of $288.83. This suggests a substantial 390.0% upside from its current price, implying that the intrinsic value of Bristol-Myers Squibb Company could be considerably higher than its market valuation. While DCF models are sensitive to inputs, this stark difference warrants a closer look for investors wondering if BMY is a good stock to add to their portfolio, especially given the market’s current assessment.

BMY financial health & key metrics

For value investors, Bristol-Myers Squibb (BMY) presents a mixed, yet intriguing, financial picture. Its P/E ratio suggests the BMY stock is trading at a discount compared to its sector, and the DCF model points to significant undervaluation. Profitability remains strong with a healthy net margin of 14.63% and excellent gross and EBITDA margins. However, a declining revenue growth of -0.2% and a relatively high debt-to-equity ratio of 2.55x are areas for caution. Despite the debt, a robust Free Cash Flow (FCF) yield of 10.7% indicates strong cash generation, which can support its attractive dividend yield.

Bristol-Myers Squibb Company earnings history & next report

Next earnings: 2026-10-29. EPS estimate: $None.

Bristol-Myers Squibb is scheduled to report its next earnings on 2026-10-29. With no specific EPS estimate provided, investors will be closely watching for updates on key product sales, particularly the performance of recent launches and established blockbusters like Revlimid and Eliquis. Focus will also be on the company’s guidance for future quarters, any progress on pipeline assets, and strategies to address the slight revenue decline. Management commentary on R&D initiatives and capital allocation, including any changes to the BMY stock dividend, will be crucial for understanding the company’s path forward.

BMY insider trading activity

Corporate insiders must report trades to the SEC within two business days.

Source: SEC Form 4 via EDGAR · Data: Financial Modeling Prep · Not investment advice

Recent BMY analyst rating changes

Bristol-Myers Squibb Company stock news today

How does BMY compare to its peers?

For investors considering BMY stock, it’s often valuable to compare its profile against other leaders in the Healthcare sector, specifically within Drug Manufacturers – General. While direct side-by-side comparison data is not provided here, examining companies with similar market positions and product portfolios can offer valuable context for BMY valuation and future prospects. Due to the absence of specific peer tickers in the provided data, a detailed comparative grid cannot be generated.

FAQ — Bristol-Myers Squibb Company (BMY) stock